CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Conference
"3TC+ABC as a NRTI Backbone" Dr. Edwin DeJesus (biography) English - 2004-05-13 - 37 minutes
(31 slides)
Summary : Despite the emergence of new antiretroviral treatments, 2-nucleoside backbone therapy remains the cornerstone for HIV treatment. Numerous clinical trials have studied lamivudine (3TC) and abacavir (ABC) in combination with NNRTIs, PIs, or NRTIs.
In this presentation Dr. DeJesus presents the results of the CNA30024 and CNA30021 studies which looked at ABC vs. ZDV BID with 3TC and EFV, and ABC QD vs. BID with 3TC and EFV.
The CNA30024 trial showed the non-inferiority of ABC compared to ZDV, with a significantly better CD4+ response in the ABC group. The CNA30021 study showed the non-inferiority of ABC QD compared to BID when combined with 3TC QD and EFV.
Copyright Š 2004 E-MedHosting.com Inc.
Learning objectives : The participant will learn the following from the CNA30024 and CNA30021 trials:
-efficacy of ABC vs. ZDV with 3TC and EFV
-efficacy of ABC QD vs. ABC BID with 3TC and EFV
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
